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Abstract
HIV-1 carrying the ‘‘Q151M complex’’ reverse transcriptase (RT) mutations (A62V/V75I/F77L/F116Y/Q151M, or Q151Mc) is
resistant to many FDA-approved nucleoside RT inhibitors (NRTIs), but has been considered susceptible to tenofovir
disoproxil fumarate (TFV-DF or TDF). We have isolated from a TFV-DF-treated HIV patient a Q151Mc-containing clinical
isolate with high phenotypic resistance to TFV-DF. Analysis of the genotypic and phenotypic testing over the course of this
patient’s therapy lead us to hypothesize that TFV-DF resistance emerged upon appearance of the previously unreported
K70Q mutation in the Q151Mc background. Virological analysis showed that HIV with only K70Q was not significantly
resistant to TFV-DF. However, addition of K70Q to the Q151Mc background significantly enhanced resistance to several
approved NRTIs, and also resulted in high-level (10-fold) resistance to TFV-DF. Biochemical experiments established that the
increased resistance to tenofovir is not the result of enhanced excision, as K70Q/Q151Mc RT exhibited diminished, rather
than enhanced ATP-based primer unblocking activity. Pre-steady state kinetic analysis of the recombinant enzymes
demonstrated that addition of the K70Q mutation selectively decreases the binding of tenofovir-diphosphate (TFV-DP),
resulting in reduced incorporation of TFV into the nascent DNA chain. Molecular dynamics simulations suggest that changes
in the hydrogen bonding pattern in the polymerase active site of K70Q/Q151Mc RT may contribute to the observed
changes in binding and incorporation of TFV-DP. The novel pattern of TFV-resistance may help adjust therapeutic strategies
for NRTI-experienced patients with multi-drug resistant (MDR) mutations.
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Introduction
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) are used
in combination with other classes of drugs for the treatment of
patients infected with human immunodeficiency virus type-1
(HIV-1). This approach is known as highly active anti-retroviral
therapy (HAART) and has been remarkably successful in reducing
the viral loads and increasing the number of CD4+ cells in
patients’ plasma. However, prolonged therapies inevitably result in
resistance to all of the available drugs. Several mutations in the
reverse transcriptase (RT) are known to cause resistance to NRTIs
through two basic mechanisms:
1) The excision mechanism, which is based on an enhanced
capacity of RT to use adenosine triphosphate (ATP) as a
n u c l e o p h i l ef o rt h er e m o v a lo ft h ec h a i n - t e r m i n a t i n g
nucleotide from the DNA terminus. The excision reaction
products are a 59,5 9-dinucleoside tetraphosphate and an
unblocked primer with a free 39-OH, allowing DNA synthesis
to resume [1,2,3]. Increased excision of NRTIs is imparted by
Excision Enhancement Mutations, typically M41L, D67N,
K70R, T215Y/F, L210W, and K219E/Q (also known as
Thymidine Associated Mutations, or TAMs). Other muta-
tions have also been reported to enhance excision, including
insertions or deletions at the tip of the b3- b4 loop of the
fingers subdomain in the background of other excision
enhancement mutations [4,5,6,7,8,9,10,11].
2) The other mechanism of NRTI resistance is the exclusion
mechanism, which is caused when NRTI-resistance muta-
tions in RT enhance discrimination and reduce incorporation
of the NRTI-triphosphate (NRTI-TP). This mechanism is
exemplified by the resistance of the M184V RT mutant to
lamivudine (3TC) and emtricitabine (FTC) due to steric clash
between the b-branched Val or Ile at position 184 and the
oxathiolane ring of the inhibitors [12,13]. Another example
of the exclusion mechanism is the multi-drug resistant (MDR)
HIV-1 RT known as Q151M complex (Q151Mc). This RT
contains the Q151M mutation together with a cluster of four
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Q151M by itself causes intermediate- to high-level resistance
to zidovudine (AZT), didanosine (ddI), zalcitabine (ddC),
stavudine (d4T), and low level resistance to abacavir (ABC)
[15,16,17] without reducing viral fitness [18,19]. Addition of
the four associated mutations increases replication capacity of
RT and results in high-level resistance to AZT, ddI, ddC, and
d4T, 5-fold resistance to ABC and low-level resistance to
lamivudine (3TC) and emtricitabine (FTC) [17,18,19,20,21].
Miller et al. and Smith et al. reported a 1.8-fold and 3.6-fold
increase in resistance to tenofovir (TFV), respectively [22,23].
Biochemical studies on the mechanism of Q151Mc resistance to
multiple NRTIs have revealed that the mutations of this complex
decrease the maximum rate of NRTI-TP incorporation without
significantly affecting the incorporation of the natural nucleotides
[21,24,25]. Structurally, the Q151 residue interacts with the 39-
OH of a normal deoxynucleoside triphosphate (dNTP) substrate
[26]. It appears that the Q151Mc mutations cause resistance to
multiple NRTIs by affecting the hydrogen bond network involving
protein side chains in the vicinity of the dNTP-binding site and the
NRTI triphosphate lacking a 39-OH [25,26,27]. The Q151Mc set
of mutations was also reported to decrease pyrophosphate PPi-
and ATP-mediated excision [25].
K65R is another mutation near the polymerase active site that
confers NRTI resistance through the exclusion mechanism.
Specifically, K65R RT has reduced susceptibility to the acyclic
nucleotide analog, TFV and other NRTIs, including ddI, ddC,
ABC, FTC and 3TC [28,29,30,31]. Biochemical studies with
K65R RT have demonstrated that this enzyme decreases the
incorporation rate of these NRTIs [32,33,34]. The crystal
structure of K65R RT in complex with DNA and TFV
diphosphate (TFV-DP) revealed that R65 forms a molecular
platform with the conserved residue R72, and the platform
enhances the ability of K65R RT to discriminate NRTIs from
dNTPs [35]. HIV carrying the Q151Mc mutations has been
reported to be susceptible to TFV disoproxil fumarate (TFV-DF),
the oral prodrug of TFV that enhances its oral bioavailability and
anti-HIV activity [22,36]. While the K65R mutation appeared in
several patients treated for more than 18 months with TFV-DF,
no patient developed multi-NRTI resistance through appearance
of Q151Mc [37].
Here we report the identification of unique HIV clinical isolates
that have acquired the K70Q mutation in the background of
Q151Mc during TFV-DF-containing therapy. We have used a
combination of virological, biochemical, and molecular modeling




HIV was isolated from fresh plasma immediately after collection
of clinical samples from study participants at the outpatient clinic
of the AIDS Clinical Center (ACC), International Medical Center
of Japan. The Institutional Review Board approved this study
(IMCJ-H13-80) and a written consent was obtained from all
participants.
Construction of recombinant clones of HIV-1
Recombinant infectious clones of HIV-1 carrying various
mutations were prepared using standard site-directed mutagenesis
protocols as described previously [38]. The NL4-3-based molec-
ular clone was constructed by replacing the pol-coding region with
the HIV-1 BH10 strain. Restriction enzyme sites Xma I and Nhe I
were introduced by silent mutations into the molecular clone at
positions corresponding to HIV-1 RT codons 15 and 267,
respectively [39]. Each molecular clone was transfected into
COS-7 cells. Cells were grown for 48 h, and culture supernatants
were harvested and stored at 280uC until use.
Single-cycle drug susceptibility assay
Susceptibilities to various RT inhibitors were determined using
the MAGIC-5 cells which are HeLa cells stably transfected with a
b-galactosidase gene under the control of an HIV long terminal
repeat promoter, and with vectors that express the CD4 receptor
and the CCR5 co-receptor under the control of the CMV
promoter as described previously [40]. Briefly, MAGIC-5 cells
were infected with diluted virus stock (100 blue forming units) in
the presence of increasing concentrations of RT inhibitors,
cultured for 48 h, fixed, and stained with X-Gal (5-bromo-4-
chloro-3-indolyl-b-D-galacto-pyranoside). The stained cells were
counted under a light microscope. Drug concentrations reducing
the number of infected cells to 50% of the drug-free control (EC50)
were determined from dose response curves.
Enzymes
RT sequences coding for the p66 and p51 subunits of BH10 were
cloned in the pRT dual vector, which is derived from pCDF-2 with
LIC duet minimal adaptor (Novagen), using restriction sites PpuMI
and SacI for the p51subunit, and SacIIand AvrII for the p66 subunit.
RT was expressed in the Escherichia coli strain BL21 (Invitrogen) and
purified by nickel affinity chromatography and MonoQ anion
exchange chromatography [41]. RT concentrations were deter-
mined spectrophotometrically based on absorption at 260 nm using
a calculated extinction coefficient (261,610 M
21 cm
21). The active
site concentration of the various RT preparations was calculated as
described below.
Nucleic acid substrates
DNA oligomers were synthesized by Integrated DNA Technol-
ogies (Coralville, IA). An 18-nucleotide DNA primer fluorescently
labeled with Cy3 at the 59 end (P18;5 9-Cy3 GTC CCT GTT
CGG GCG CCA-39) and a 100-nucleotide DNA template (T100;
59-TAG TGT GTG CCC GTC TGT TGT GTG ACT CTG
GTA ACT AGA GAT CCC TCA GAC CCT TTT AGT CAG
TGT GGA AAA TCT CTA GCA GTG GCG CCC GAA CAG
GGA C-39) were used in primer extension assays. An 18-
nucleotide DNA primer 59-labeled with Cy3 (P18;5 9-Cy3 GTC
ACT GTT CGA GCA CCA-39) and a 31-nucleotide DNA
template (T31;5 9- CCA TAG CTA GCA TTG GTG CTC GAA
CAG TGA C-39) were used in the ATP rescue assay and pre-
steady state kinetic experiments.
Active site titration and determination of the dissociation
constant for DNA binding (KD-DNA)
Determination of active site concentrations in the different
preparations of WT and mutant RTs were performed using pre-
steady state burst experiments. A fixed concentration of RT
(80 nM, determined by absorbance measurements) was pre-
incubated with increasing concentrations of DNA/DNA tem-
plate/primer (T31/P18), followed by rapidly mixing with a reaction
mixture containing MgCl2 and dATP, at final concentrations of
5 mM and 50 mM, respectively. The reactions were quenched at
various times (10 ms to 5 s) by adding EDTA to a final
concentration of 50 mM. The amounts of product (P18-dAMP)
were quantitated and fit to the following burst equation:
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where A is the amplitude of the burst phase that represents the RT-
DNA complex at the start of the reaction, kobs is the observed burst rate
constant for dNTP incorporation, kss is the steady state rate constant,
and tis the reaction time. The rate constant of the linear phase (kcat)c a n
be estimated by dividing the slope of the linear phase by the enzyme
concentration. The active site concentration and template/primer
binding affinity (KD-DNA) were determined by plotting the amplitude
(A) against the concentration of template/primer. The data were fit
using non-linear regression to a quadratic equation:
A~0:5 KDz RT ½  z DNA ½  ðÞ {
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:25 KDz RT ½  z DNA ½  ðÞ
2{ RT ½  DNA ½  ðÞ
q ð2Þ
where KD is the dissociation constant for the RT-DNA complex, and
[RT] is the concentration of active polymerase molecules. Subsequent
biochemical experiments were performed using corrected active site
concentrations [42,43].
Primer extension assay
To examine the DNA polymerase activity of WT and mutant
RTs and the inhibition of DNA synthesis by TFV, the primer
extension assays were carried out on the T100/P18 template/
primer (P18 was 59-Cy3 labeled) in the presence or absence of
3.5 mM ATP [41]. The enzyme (20 nM active sites) was
incubated with 20 nM template/primer at 37uC in a buffer
containing 50 mM Tris-HCl, pH 7.8 and 50 mM NaCl. The
DNA synthesis was initiated by the addition of 1 mM dNTP and
10 mM MgCl2. The primer extension assays were carried out in
the presence or absence of varying concentrations of TFV-DP.
The reactions were terminated after 15 min by adding equal
volume of 100% formamide containing traces of bromophenol
blue. The extension products were resolved on a 7 M urea-15%
polyacrylamide gel, and visualized by phosphor-imaging (FLA
5100, Fujifilm, Tokyo). We followed standard protocols that utilize
the Multi Gauge software (Fujifilm) to quantitate primer extension
[41,44]. The results from dose response experiments were plotted
using Prism 4 (GraphPad Software Inc., CA) and IC50 values for
TFV-DP were obtained at midpoint concentrations.
ATP-dependent rescue assay
Template/primer (T31/P18) terminated with TFV (T/PTFV)w a s
prepared as described in Michailidis et al [41]. 20 nM of T/PTFV
was incubated at 37uC with HIV-1 RT (60 nM), either at various
concentrations of ATP (0–7 mM) for 30 minutes, or for various
times (0–120 minutes) with 3.5 mM ATP, in RT buffer containing
50 mM Tris-HCl, pH 7.8, and 50 mM NaCl, and 10 mM MgCl2.
TheassaywasperformedinthepresenceofexcesscompetingdATP
(100 mM) that prevented reincorporation of the excised TFV,
0.5 mM dTTP and 10 mM ddGTP. Reactions were quenched with
100% formamide containing traces of bromophenol blue and
analyzed as described above. The dissociation constants (Kd) of the
various enzymes for ATP used in the rescue reactions were
determined by fitting the rescue data at various ATP concentra-
tions, using non-linear regression fitting to hyperbola.
Kinetics of dNTP incorporation by WT and mutant
enzymes
To determine the binding affinity of WT and mutant enzymes
to the dNTP substrate (KD-dNTP) and to estimate the maximum
rate of dNTP incorporation by these enzymes (kpol), we carried out
transient-state experiments using a rapid quench instrument
(RQF-3, Kintek Corporation, Clarence, PA) at 37uCi nR T
buffer (50 mM Tris-HCl, pH 7.8 and 50 mM NaCl). HIV-1 RT
(50 nM active sites) was pre-incubated with 50 nM T31/P18 in one
syringe (Syringe A), whereas varying concentrations of dNTP and
10 mM MgCl2 were kept in another syringe (Syringe B). The
solutions were rapidly mixed to initiate reactions, which were
subsequently quenched at various times (5 ms to 10 s) by adding
EDTA to a final concentration of 50 mM. The products from
each quenched reaction were resolved, quantitated, and plotted as
described above. The data were fit by non-linear regression to the
burst equation (Eq 1).
To obtain the dissociation constant KD-dNTP for dNTP binding
to the RT-DNA complex, the observed burst rates (kobs) were fit to
the hyperbolic equation (Eq. 3) using nonlinear regression:
kobs~ kpol dNTP ½ 
  
= KD{dNTPz dNTP ½  ðÞ ð 3Þ
where kpol is the optimal rate of dNTP incorporation.
The kinetics of TFV incorporation by the WT and mutant
enzymes were carried out in a manner similar to that employed for
natural dNTP substrate except the time of reactions. It was noted
that the mutant enzymes required longer time to incorporate TFV
compared to the WT HIV-1 RT (detailed in the Results section).
Molecular Modeling
Molecular models of mutant enzymes were generated using
SYBYL (Tripos Associates, St. Louis, MO). The starting protein
coordinates were from the crystal structure of HIV-1 RT in
complex with DNA template/primer and TFV-DP (PDB file
1T05) [45]. They were initially modified by the Protein
Preparation tool (Schrodinger Molecular Modeling Suit, NY),
which deletes unwanted water molecules, sets charges and atom
type of metal ions, corrects misoriented Gln and Asn residues, and
optimizes H-atom orientations. Amino acid side chains were
substituted in by Maestro (Schrodinger, Molecular Modeling
Suite, NY). Molecular dynamics simulations of the WT and
mutant RT models were carried out to obtain the most stable
structures by Impact, interfaced with Maestro at constant
temperature, and OPLS_2005 force field. The molecular
dynamics simulations were performed for 1000 steps with
0.001 ps intervals. The temperature relaxation time was 0.01 ps.
The Verlet integration algorithm was used in simulations. The
structures were imported into Pymol (http://www.pymol.org) for
visualization and comparison.
Results
Phenotypic resistance to TFV-DF in the absence of any
known TFV resistance mutations
During phenotypic and genotypic evaluation of the clinical
isolates we identified a unique virus that exhibited an apparent
discordance between the phenotypic and genotypic results. The
clinical history of the patient and the corresponding genotypic and
phenotypic changes during the course of the therapy are
summarized in Fig. 1. (Also see Table S1). The patient’s treatment
before Feb 2002 included d4T, ddI, and EFV and did not decrease
significantly the viral loads (Fig 1A). Hence, the therapeutic
regimen was switched to TFV-DF, EFV, and the protease
inhibitor lopinavir (LPV). However, the patient’s immunological
and virological responses still did not improve due to poor
adherence, especially to LPV. Genotypic and phenotypic analyses
on March 2002 (point 1) and June 2002 (point 2) revealed
K70Q Expands MDR of Q151M Complex HIV-1 RT
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Resistance to all NRTIs, except AZT and FTC, was enhanced in
the point 2 isolate (Fig. 1B). Notably, this isolate showed an
increase in resistance to TFV-DF in the absence of the canonical
TFV resistance mutation (K65R) and in the presence of Q151Mc
mutations (Fig. 1C). Previously, it has been shown that Q151Mc
remains susceptible to TFV [22] although Smith et al. reported
that Q151Mc had a 3.6-fold increase in TFV resistance [23].
Suppression of the viral load was finally achieved by improvement
in drug adherence to LPV and by the addition of FTC in the
therapeutic regimen, since no protease resistance mutations were
found within the protease coding region.
To identify the mutation(s) responsible for the unexpected
resistance to TFV-DF we sequenced the entire RT coding region
at time-points 1 and 2 (Figure S1, GenBank Accession Number
AB506802 and AB506803). Of the three substituted residues (70,
102, and 108) amino acids 102 and 108 are part of the structurally
distinct NNRTI binding pocket [46], which can mutate during
EFV-based therapeutic regimens. However, residue 70 is located
in the b3-b4 hairpin loop of the p66 ‘‘fingers’’ subdomain of HIV-
1 RT, which interacts with the incoming dNTP substrate [10,27].
Different mutations at this site have been previously implicated in
NRTI resistance [47], suggesting that the observed K70Q
mutation may be involved in the increased resistance to TFV-DF.
NRTI resistance enhancement by mutation at residue 70
Severalmutations at position 70 of HIV-1 RT (R, G, E, T, N and
Q) have been reported to the Stanford HIV-1 Drug Resistance
Database (http://hivdb.stanford.edu/, accessed on Feb. 27
th 2010).
K70Q is rarely observed in treatment-naı ¨ve patients (0.04%), but
appears more often in clinical samples from NRTI-treated patients
(0.1%, p,0.0001 compared with the frequency of K70Q in
treatment-naı ¨ve patients) but not NNRTI-treated patients. Fur-
thermore, K70Q is observed in 0.5% of the clinical samples from
patients infected with HIV-1 Q151M. There have been no previous
reports on a possible role of K70Q in NRTI resistance.
To examine the effect of K70Q on drug susceptibility we
generated a series of HIV variants with mutations at RT codon 70
(Figure 2A and also Table S2). The HIV-1K70Q variant exhibited
marginal resistance to ddI and 3TC (5- and 3.3-fold, respectively),
but no significant resistance to other NRTIs. We further examined
whether the mutations at residue 70 affect susceptibility to
NRTIs in the Q151Mc background (Figure 2B and also Table
S3). HIV-1K70G/Q151Mc had enhanced resistance to d4T (4.6-fold)
as compared to HIV-1Q151Mc. Notably, HIV-1K70Q/Q151Mc also
showed enhanced resistance to ddI and d4T (2.4- and 4.4-
fold, respectively, compared to HIV-1Q151Mc). In addition,
HIV-1K70Q/Q151Mc displayed 5-fold increased resistance to TFV-
DF compared to HIV-1Q151Mc. Other K70 mutations exhibited
little or no resistance to TFV-DF.
Primer Extension and ATP-based Rescue Assays
As mentioned earlier, a key mechanism of NRTI resistance is
the excision mechanism, which is based on the enhanced ability of
NRTI-resistant enzymes to use ATP for unblocking chain-
terminated primers and allow for further DNA synthesis to
continue [2,3,48]. To determine whether the K70Q mutation
causes TFV resistance through the excision mechanism we
measured the susceptibility of WT and mutant RTs to inhibition
by TFV in the presence or absence of ATP. In gel-based assays, an
enhancement in excision would manifest as an increase in the
production of fully extended DNA when 3.5 mM ATP is included
in the extension reaction [49,50]. Our extension assays in the
absence of ATP (no-excision conditions) showed that addition of
the K70Q mutation to Q151Mc HIV-1 RT enhances resistance to
TFV-DP. However, this enhancement is not influenced by the
presence of ATP (Table 1, Fig. 3A and Figure S2A). In fact,
excision enhancement due to the presence of ATP measured as
[IC50 with ATP]/[IC50 without ATP] was similar for all enzymes,
including the WT RT (from 2.7-fold to 2.9-fold for WT, K70Q,
Q151Mc, and K70Q/Q151Mc RTs) (Table 1). Using a related
type of assay, the ATP-mediated rescue assay, we compared the
rates by which the WT and mutant RTs unblock TFV-terminated
primers and extend products past the point of chain-termination.
We find that the ATP-based rescue activity of WT RT is not
slower, but 1.5-, 2.5-, and 3-fold faster than that of K70Q,
Q151Mc, and K70Q/Q151Mc RTs, respectively (Fig. 3B and
Figure S2B). In addition, the ATP-based rescue activity of WT RT
was saturated at lower concentrations of ATP than K70Q,
Figure 1. Clinical course of patient and drug resistance profile.
(A) The two clinical isolates were collected from the patient at the time
points indicated by triangles. Both isolates had no known resistant
mutations in the protease region. During the period indicated by
asterisk, LPV was administrated but the patient demonstrated poor
adherence due to undesirable side effects. After instruction on the use
of antiretroviral drugs, the viral loads successfully decreased below the
detection limit (,50 copies/ml). (B) Phenotypic drug susceptibility
assays of clinical isolates in at least three independent experiments are
shown as a relative increase in EC50 compared to HIV-1 NL4-3 strain
which served as WT (see also Table S1). (C) Mutations observed in the
isolates that are defined as the NRTI and NNRTI resistance associated
mutations deposited in the HIV Drug Resistance Database maintained
by International AIDS Society 2009 [58] and the Stanford University
(http://hivdb.stanford.edu/) were shown. Abbreviations of drugs used:
d4T, stavudine; ddI, didenosine; EFV, efavirenz; TFV-DF, tenofovir
disoproxil fumarate; LPV, lopinovir; AZT, zidovudine; 3TC, lamivudine;
ABC, abacavir; FTC, emtricitabine; NVP, nevirapine.
doi:10.1371/journal.pone.0016242.g001
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carrying mutations at residue 70 (K70R, K70G, K70E, K70T, K70N, or K70Q) in the WT (A) or Q151Mc (B) background were determined by the MAGIC5
assay. The data for each clone were compared to WT (A) and Q151Mc (B) HIV-1 and are shown as fold increase; AZT (red), ddI (green), d4T (cyan), 3TC
(orange), ABC (blue), and TFV-DF (purple). Error bars represent standard deviations from at least three independent experiments (see also Table S2
and S3). The asterisk indicates statistically significant in EC50 values (P,0.0001 by t-test).
doi:10.1371/journal.pone.0016242.g002
Table 1. Primer extension assay in the presence or absence of ATP.
Enzymea IC50 (nM) of TFV-DP
b (fold increase
c) Excision enhancement due to ATP
d
Without ATP With ATP




K70Q 802699 23066270 2.9
(1.3) (1.2)
Q151Mc 1503690 39966341 2.7
(2.3) (2.1)
K70Q/Q151Mc 23926353 70016226 2.9
(3.7) (3.8)
a.The sequence of HIV RT WT and mutant derived from BH10.
b.Data are means 6 standard deviations from at least three independent experiments.
c.The relative increase in IC50 value compared with each HIV-1 RT WT without, or with ATP is given in parentheses. Bold indicates an increase in fold increase value
greater than 3-fold.
d.Excision enhancement due to ATP is calculated as IC50 with ATP/IC50 without ATP.
doi:10.1371/journal.pone.0016242.t001
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WT, K70Q, Q151Mc and K70Q/Q151Mc were 0.4, 0.7, 2.3,
and 3.1 mM, respectively), suggesting that a better binding of ATP
may contribute to the slightly enhanced excision activity of WT
RT (Fig. 3C and Figure S2C). Collectively, these results rule out
the possibility that K70Q/Q151Mc becomes resistant to TFV
through the excision mechanism.
Pre-Steady Kinetic Constants for Binding and
Incorporation of dATP and TFV-DP
To determine whether the resistance by K70Q/Q151Mc is
caused by an increased preference of physiological dATP substrate
over TFV-DP, we carried out pre-steady state transient kinetic
analyses of WT, K70Q, Q151Mc, and K70Q/Q151Mc enzymes.
The kinetic constants kpol-dATP and KD-dATP for WT and mutant
Figure 3. Effects of RT mutations K70Q, Q151Mc, or K70Q/Q151Mc on DNA primer extension activity and on ATP-based excision
activities. (A) Effect of varying concentrations of TFV-DP on the primer extension activities of HIV-1 WT and mutant RTs. The experiments were
carried out in the presence (&) or absence (m) of 3.5 mM ATP (B) Time dependence of ATP-based rescue of TFV-terminated primers. TFV-terminated
T31/P18 oligos (20 nM) were incubated with 60 nM RT and 3.5 mM ATP. The reaction mixture also included excess of competing dATP (100 mM) that
prevented reincorporation of TFV-DP and 0.5 mM dTTP, and 10 mM ddGTP that allowed extension of the rescued primer by two nucleotides and chain
termination. Rescue products (WT [&], K70Q [m], Q151Mc [.] and K70Q/Q151Mc [¤]) were analyzed at indicated time points. (C) ATP-based rescue
was dependent on concentration of ATP. Reactions were as in (B), but for 30 minutes and at varying concentrations of ATP. Rescue products at 7 mM
ATP are defined as 100% product formed.
doi:10.1371/journal.pone.0016242.g003
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S3). The results reveal that K70Q, Q151Mc, and K70Q/
Q151Mc RTs have increased kpol-dATP as well as KD-dATP. Both
Q151Mc and K70Q/Q151Mc enzymes incorporate dATP faster
than WT (17.9 and 14.6 s
21, respectively vs. 6.3 s
21) but have a
weaker binding affinity for dATP than WT RT (5.4 and 5.0 mM,
respectively vs. 2.6 mM). Hence, the catalytic efficiency ratio of
dATP incorporation remains similar for all enzymes (kpol-dATP/KD-
dATP ratios for WT, K70Q, Q151Mc, and K70Q/Q151Mc were
2.4, 2.2, 3.3, and 2.9 mM
21?s
21, respectively). On the contrary, a
significant change in the incorporation efficiency of TFV was
observed. The K70Q and K70Q/Q151Mc enzymes had more
than 4.5-fold reduced affinity for TFV than the WT enzyme
(KD-TFV values were 8.6 and 8.9 mM compared to 1.9 mM). In
addition, the turnover rates of TFV incorporation by the WT and
K70Q enzymes were comparable (kpol-TFV were 2.8 and 3.1 s
21,
respectively). The addition of the K70Q mutation to Q151Mc also
reduced the kpol for TFV-DP. The net effect of these changes was a
significant reduction in the TFV-DP incorporation efficiencies of
the mutant enzymes compared to the WT enzyme (kpol-TFV/
KD-TFV ratios for WT, K70Q, Q151Mc, and K70Q/Q151Mc
were 1.47, 0.36, 0.3, and 0.11 mM
21?s
21, respectively; Table 2).
WT RT incorporated TFV-DP most efficiently, followed by
K70Q.Q151Mc.K70Q/Q151Mc enzymes. As a direct mea-
sure of the enzyme’s ability to discriminate between the natural
dATP substrate and the TFV, we determined the ‘‘selectivity’’,
defined as the ratio of efficiency of the enzyme to incorporate
dATP over TFV-DP (kpol-dATP/KD-dATP/kpol-TFV/KD-TFV). The
selectivity values demonstrate that the K70Q/Q151Mc enzyme
favors incorporation of dNTP over TFV-DP 26.3 times compared
to 1.6 times by the WT enzyme, leading to a 16.4-fold resistance to
TFV (defined as selectivitymutant/selectivityWT; Table 2). This
resistance is more than twice the TFV resistance of Q151Mc and 4
times the TFV resistance of K70Q.
Molecular modeling
Molecular dynamics simulations on the control structural
coordinates of the WT RT/DNA/TFV-DP crystal structure
[45] did not cause any significant structural changes, suggesting
that the modeling protocols do not alter the structures in ways that
are not related to the K70Q or Q151Mc mutations. The root
mean square deviation (rmsd) between the Ca atoms of the WT
structures before and after simulation was 0.1 A ˚. Similarly, the
rmsd between the Ca atoms of WT and mutant RT molecular
models were also very low (,0.1 A ˚). Comparison of these models
showed a significant repositioning of residue 65 in Q151Mc/
K70Q (Fig. 5), and to a lesser extent in K70Q or Q151Mc RTs
(not shown). Additional smaller changes in the side chains of
residues 151, 70, and 72 were also observed (Fig. 5). The structure
of TFV-DP was also slightly adjusted, possibly as a result of the
changes in the surrounding residues (Fig. 5). While residue 70 is
located proximal to residue 65, and to the phosphates of the
incoming TFV-DP, it does not appear to interact directly with
these structural elements.
Discussion
We have discovered a novel HIV mutation that causes high-
level resistance to TFV-DF. We have also determined the
biochemical mechanism of this resistance. TFV-DF is a valuable
NRTI therapeutic option for patients infected with multi-drug
resistant Q151Mc HIV-1 [22]. We demonstrate here that
Q151Mc can acquire an additional mutation, K70Q, which
expands the multi-drug resistance to include high-level resistance
to TFV-DF. We identified this mutant during genotypic analysis of
clinical isolates from an HIV-infected patient who was not
responding to TFV-DF. The K70Q/Q151Mc set of mutations is
currently rare among HIV-infected patients. However, we believe
that similar to K65R, its prevalence will increase, as tenofovir use
continues to rise. Our virological studies with recombinant viruses
confirmed that the observed enhancement and expansion of multi-
drug resistance is the consequence of the addition of K70Q to
Q151Mc HIV. Recently, the concept of clinical cut-offs (CCOs)
has been introduced to improve the prediction of drug resistance
during antiretroviral therapies. CCOs are better correlated with
virologic response than biological cut-offs [51,52]. Importantly,
K70Q/Q151Mc is 10 times less susceptible to TFV-DF than WT
HIV-1, whereas the CCOs for TFV-DF is defined as a 2.1-fold
reduction in virologic response to this inhibitor. Moreover,
K70Q/Q151Mc is at least twice as resistant to TFV as the well-
known TFV-resistant K65R in the background of Q151Mc (as
reported in the Stanford HIV Drug Resistance Database).
Previous studies have offered insights into the drug resistance
mechanism of similar mutations (K70E, K70G, K70R, and
K70T). Specifically, K70E was selected in patients with virological
failure after TFV-DF-based antiviral therapy [53,54,55]. K70T
emerged in the background of Q151Mc during in vitro selection by
TFV-DF [56]. K70R is a key mutation involved in resistance to
AZT and appears in the background of other excision enhance-
ment mutations [2,3,57]. In our case, a new mutation (K70Q) was
Table 2. Pre-steady state kinetic constants for binding and incorporation of dATP and TFV-DP by WT, K70Q, Q151Mc and K70Q/
Q151Mc HIV-1 RT.
Pre-steady state kinetic constants
a
Enzyme




21)K d (mM) kpol/Kd (mM
21?s
21) kpol (s
21)K d (mM) kpol/Kd (mM
21?s
21)
WT 6.360.5 2.660.1 2.460.2 2.860.08 1.960.2 1.4760.07 1.6 -
K70Q 8.460.4 3.860.6 2.260.4 3.160.4 8.661.5 0.3660.08 6.1 3.8
Q151Mc 17.960.4 5.460.5 3.360.3 1.360.03 4.360.8 0.360.06 11 6.9
K70Q/Q151Mc 14.661.6 5.060.07 2.960.3 1.060.03 8.962.1 0.1160.03 26.3 16.4
a.Data are means 6 standard deviations from at least three independent experiments.
b.The sequence of HIV RT WT and mutant derived from BH10.
c.Selectivity is defined as (kpol/Kd)dATP/(kpol/Kd)TFV-DP.
d.Resistance (fold) is calculated as selectivity mutant/selectivity WT.
doi:10.1371/journal.pone.0016242.t002
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course of TFV-DF-based antiviral therapy. The International
AIDS Society-USA publishes [58] every year a list of HIV-1 drug
resistance mutations compiled by a panel of experts charged with
the goal of delivering accurate, unbiased, and evidence-based
information for use by HIV clinical practitioners. In order for a
novel mutation to be accepted in the list it should meet at least one
of the following criteria: 1) in vitro passage experiments or
Figure 4. Pre-steady state kinetics of incorporation of dATP or TFV-DP by WT and K70Q/Q151Mc HIV-1 RTs. Single-nucleotide
incorporation of dATP (panels A, B, and E) or TFV-DP (panels C, D, and F) by WT (panels A, C, E, and F) and K70Q/Q151Mc (panels B, D, E, and F).
Formation of extended primer products in the reactions with WT RT and K70Q/Q151Mc RT were measured at 5 ms to 5 s time points, using the
following dATP concentrations: 0.5 (&), 1 (%), 2.5 (m), 5 (*), 10 (¤), 20 (e), 50 (.) and 75 mM( +). Incorporation of TFV was measured at 0.1–10 s
reactions and at the following TFV-DP concentrations: 0.75 (&), 1.5 (%), 3.75 (m), 7.5 (*), 15 (¤), 37.5 (e) and 75 mM( +) for reactions with WT RT
(panel C), and 1.5 (%), 7.5 (*), 15 (¤), 37.5 (e), 55 (.), 75 (+), 112.5 (N), 150 (#) and 200 mM (x) for reactions with K70Q/Q151Mc RT (panel D). (E) The
amplitudes of the burst phases from the dATP reactions shown in panels A (WT, [¤]) and B (K70Q/Q151Mc, [&]) were plotted as a function of dATP
concentrations. (F) The amplitudes of the burst phases from the TFV-DP reactions shown in panels C (WT, [¤]) and D (K70Q/Q151Mc, [&]) were
plotted as a function of TFV-DP concentrations. The solid lines in panels A, B, C, and D represent the best fit of data to the burst equation. Each point
represents the average values of three experiments.
doi:10.1371/journal.pone.0016242.g004
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mutagenesis; 2) susceptibility testing of laboratory or clinical
isolates; 3) nucleotide sequencing of viruses from patients in whom
the drug is failing; 4) correlation studies between genotype at
baseline and virologic response in patients exposed to a drug. Our
study has unambiguously demonstrated that K70Q meets at least
the first three criteria: evidence for criterion #1 is shown in
Figure 2; for criterion #2 in Figures 1 and 2; and for criterion #3
in Figure 1 and Figure S1. Therefore, the K70Q mutation meets
the criteria of a clinically relevant mutation.
In addition to the clinical and virological studies, we used
biochemical techniques to determine the mechanism of TFV
resistance imparted by the K70Q mutation to Q151Mc RTs. We
used primer extension assays to show that K70Q/Q151Mc RT is
less susceptible to TFV-DP than WT and Q151Mc RTs. We
demonstrated that the mechanism of this resistance is not based on
excision. On the contrary, we showed that the ATP-based excision
of the mutant enzymes was slightly decreased with respect to WT
RT, possibly because of decreased affinity of the mutant enzymes
for the ATP excision substrate, incurred by changes in the binding
environment of ATP, such as the loss of lysine at position 70.
Using transient-state kinetics we unambiguously established that
the overall mechanism of K70Q/Q151Mc resistance to TFV is
due to enhanced discrimination between the natural dATP
substrate and TFV-DP. While all mutant enzymes had compara-
ble efficiency of dATP incorporation, they displayed varying
affinity and turnover rates of incorporation. It appears that the
stronger effect of the enhanced discrimination overcomes the slight
increase in sensitivity due to the small increase in excision. As a
result, the mutant enzymes are resistant to the inhibitor.
Mutations at position 70 of RT have been known to confer
NRTI resistance by two distinct mechanisms: K70R combined
with at least two excision enhancing mutations, D67N and T215Y,
enhances ATP-mediated excision of AZT and d4T [1,2,3,48]
(excision–dependent mechanism). On the other hand, K70E causes
resistance to 3TC, TFV, and ABC by lowering the maximum rate
of inhibitor incorporation by RT (kpol-dependent exclusion mechanism)
[55]. Our results establish that in the background of Q151Mc,
K70Q causes TFV resistance through a third mechanism: by
decreasing the binding affinity of the inhibitor (Kd-dependent
exclusion mechanism). Taken together, these findings highlight the
remarkable ability of RT to use separate mutations at a single
position to acquire NRTI resistance through three different
mechanisms.
Our cell-based assays with infectious HIV-1 show that Q151Mc
remains susceptible to TFV-DF, a finding consistent with previous
reports [22]. Similarly, clinical isolates deposited at the Stanford
HIV resistance database and carrying the Q151Mc mutation were
also susceptible to TFV-DF, unless they also had the K65R
mutation. However, pre-steady state characterization of TFV-DP
incorporation by Q151Mc in this work (Table 2) and by others
[59] showed that Q151Mc is less susceptible to TFV-DP than WT
RT. This small discrepancy may be the result of potential
differences in DNA-dependent and RNA-dependent DNA
synthesis, or the result of the slightly increased excision of
Q151Mc RT compared to WT RT (Fig. 3B and C).
To gain insights into the possible structural changes caused by
the addition of K70Q to Q151Mc, we compared the molecular
model of K70Q/Q151Mc RT/DNA/TFV-DP with the crystal
structure of WT RT/DNA/TFV-DP [45] (Fig. 5). The network of
hydrogen bonds involving the side-chains of K65, R72, and Q151
in the WT structure [26,27,54], is disrupted in the mutant
structure. Also, Q151M and associated mutations A62V, V75I,
and F77L are likely to modify the hydrophobic core of the fingers.
We and others have previously shown that the side-chains of
residues 72 and 65 interact with each other [35] and with Q151
Figure 5. Stereo view of TFV-DP in the polymerase active site of WT RT and K70Q/Q151Mc RT. WT RT residues are shown as cyan sticks,
K70Q/Q151Mc RT residues are shown as purple sticks. The primer strand is shown as dark gray sticks, template strand as light gray sticks. The fingers
and palm subdomains are shown as blue and red cartoons, respectively.
doi:10.1371/journal.pone.0016242.g005
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DP [45]. The functions of these residues have been established by
several biochemical studies [21,25,60,61,62,63]. The reduction in
polymerase rate (kpol) and in binding affinity for TFV-DP
(increased Kd.TFV-DP) may be the consequence of one or more
such structural changes. Our molecular dynamics simulation
experiments suggested a re-arrangement in the position of the side
chain of K65, which is a catalytically important residue. While the
precise effect of this change is not clear at this point, such changes
could influence the overall binding of the substrate and/or the rate
of nucleotide incorporation. Moreover, such movement of K65 in
the presence of a mutation at position 70 is consistent with our
previously reported crystallographic data, which established that
there is an interplay between the positioning of the side chains at
positions 70 and 65 [64]. Ongoing crystallographic studies are
expected to provide more detailed structural insights into the role
of K70Q in drug resistance.
In summary, we report here clinical data showing that addition
of the K70Q mutation to the Q151Mc background confers high-
level HIV resistance to TFV-DF and enhances resistance to other
NRTIs. The biochemical mechanism of the TFV resistance is
based on reduced binding affinity and incorporation of TFV-DP.
Detection of this novel pattern of TFV-DF resistance may help
adjust therapeutic regimens for the treatment of patients infected
with multi-drug resistant HIV-1.
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Figure S1 Amino acid sequence alignment of the RT regions
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Figure S2 Effects of RT mutations K70Q, Q151Mc, or K70Q/
Q151Mc on DNA primer extension activity and on ATP-based
excision activities. (A) Effect of varying concentrations of TFV-DP
on the primer extension activities of HIV-1 WT and mutant RTs.
The experiments were carried out in the presence and absence of
3.5 mM ATP (marked as ATP (+) and ATP (2), respectively).
Addition of ATP in the polymerization mixture allows measure-
ment of the net sum of DNA polymerization and ATP-based
excision activities. (B) Time dependence of ATP-based rescue of
TFV-terminated primers. (C) ATP-based rescue was dependent on
concentration of ATP.
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Figure S3 Pre-steady state incorporation of dATP or TFV-DP
by K70Q and Q151Mc HIV-1 RTs. Single-nucleotide incorpo-
ration of dATP (panels A, B, and E) or TFV-DP (panels C, D, and
F) by K70Q (panels A, C, E, and F) and Q151Mc (panels B, D, E,
and F). Formation of extended primer products in the reactions
with K70Q RT and Q151Mc RT were measured at 5 ms to 5 s
time points, using the following dATP concentrations: 0.5 (&), 1
(%), 2.5 (m), 5 (*), 10 (¤), 20 (e), 50 (.) and 75 mM( +).
Incorporation of TFV was measured at 0.1–10 s reactions and at
the following TFV-DP concentrations: 0.75 (&), 1.5 (%), 3.75 (m),
7.5 (*), 15 (¤), 37.5 (e) and 75 mM( .) for reactions with K70Q
RT (panel C), and 3.75 (m), 7.5 (*), 37.5 (e), 55 (.), 75 (+) and
112.5 (N) for reactions with Q151Mc RT (panel D). (E) The
amplitudes of the burst phases from the dATP reactions shown in
panels A (K70Q, [m]) and B (Q151Mc, [.]) were plotted as a
function of dATP concentrations. (F) The amplitudes of the burst
phases from the TFV-DP reactions shown in panels C (K70Q,
[m]) and D (Q151Mc, [.]) were plotted as a function of TFV-DP
concentrations. The solid lines in panels A, B, C, and D represent
the best fit of data to a burst equation. Each point represents
average values of three experiments.
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